Related Experiment Video

Updated: Aug 4, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

French expert group proposal for lipid-lowering therapy in the first 3 months after acute myocardial infarction

François Schiele1,2, Pierre Sabouret3, Etienne Puymirat4

  • 1Department of Cardiology, University Hospital of Besancon, Besancon, France - francois.schiele@univ-fcomte.fr.

Panminerva Medica
|April 6, 2023
PubMed

Insights

This study proposes a French expert strategy for rapid lipid-lowering therapy in acute myocardial infarction (MI) patients. The goal is to quickly reduce LDL cholesterol (LDL-c) and improve cardiovascular outcomes.

Area of Science:

  • Cardiology
  • Lipidology
  • Pharmacology

Background:

  • Reducing LDL cholesterol (LDL-c) in acute myocardial infarction (MI) patients is linked to fewer major adverse cardiovascular events.
  • Effective lipid management is crucial for post-MI recovery and secondary prevention.

Purpose of the Study:

  • To present a French expert consensus proposal for optimizing lipid-lowering therapy during the acute phase of myocardial infarction.
  • To establish a strategy for early achievement of target LDL-c levels in hospitalized MI patients.

Main Methods:

  • Development of a consensual proposal by a multidisciplinary French expert group (cardiologists, lipidologists, GPs).
  • Outline of a therapeutic strategy involving statins, ezetimibe, and PCSK9 inhibitors.
  • Focus on rapid implementation and achieving target LDL-c levels early.

Main Results:

  • A feasible and practical lipid-lowering strategy for acute MI patients in France.
  • The proposed approach aims for significant and rapid LDL-c reduction.
  • Anticipated improvement in lipid management for acute coronary syndrome (ACS) patients.

Conclusions:

  • The proposed strategy offers a simple, rapid, and effective method for managing lipids in acute MI.
  • Early and aggressive LDL-c reduction is key to improving cardiovascular outcomes post-MI.
  • This expert-driven approach can enhance clinical practice in France for post-MI lipid management.

More Related Videos

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.4K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.3K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
719
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
12
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
17
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
18
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
27